அஸ்ஸ் ஆர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from அஸ்ஸ் ஆர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In அஸ்ஸ் ஆர் Today - Breaking & Trending Today
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the launch of its IBS-D Clinical Trial recruitment website. ....
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities. ....
Q3 FY21 Activities ReportMelbourne, April 27, 2021 AEST (ABN Newswire) - Anatara Lifesciences ( ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company s Appendix 4C cash flow report. Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have successfully progressed two key milestones during the period - a successful trial for Anatara s proprietary enriched formulation for poultry in water, and ethics approval to start the human IBS trial. Anatara now has approval to commence two separate human trials for its Gastrointestinal Re-Programming complementary medicine (GaRP), and there appears to be a wider appreciation of the Company s human health initiatives and the potential to improve overall human wellbeing with ....
Anatara Lifesciences Ltd (ASX:ANR) Announces Australian Patent Grant for Detach
Announces Australian Patent Grant for DetachMelbourne, April 16, 2021 AEST (ABN Newswire) - Anatara Lifesciences Ltd ( ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled Anti-diarrhea formulation which avoids antimicrobial resistance . - Granting of patent number AU2019204496 strengthens Anatara s intellectual property position (IP) in the treatment and prevention of diarrhea caused by pathogenic microbes - The patent provides the pathway for Anatara to further pursue commercialisation opportunities for Detach(R) - Patent expires on 24 August 2038 - Piglet challenge study commenced Anatara s animal heath product, Detach(R), uses the patent as a non-antibiotic approach to aid in the control of diarrheal disease (known as scour), developed using bromelain, an extract from pineapple stems. ....
Anatara Receives Ethics Approval to Start IBS TrialMelbourne, Feb 8, 2021 AEST (ABN Newswire) - Anatara Lifesciences ( ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D). Highlights: - Study design is Randomised, Double-Blinded and Placebo-Controlled to address future evidence-based claims - Virtual study with ObvioHealth Australia to provide digital clinical trial platform ClaimIt - Supported by leading CROs: GenesisCare Clinical CRO, Microba, Sonic Clinical Trials ....